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SUMMARY
We conducted a retrospective analysis of Toxoplasma encephalitis patients from Instituto de Infectologia Emílio Ribas, the main
AIDS hospital of São Paulo, Brazil, during two different stages of the HIV epidemics, in 1988 (38 patients) and 1991 (33 patients).
There were AIDS-related demographic differences, but the clinical presentation and diagnostic efficiency were similar, usually based
on tomography and clinical response to therapy, with a clear distinction from other CNS infections, based on clinical and laboratory
findings. Specific serologic studies were performed less often in 1991, with a high frequency of therapy change. The direct acute
death rate from Toxoplasma encephalitis was high during both periods, i.e. 8/38 in 1988 and 10/33 in 1991. The direct acute death rate
for the patients from the two periods as a whole was 25.4% (18/71), related to the time of HIV infection, absence of fever and presence
of meningeal irritation at presentation, blood leukocytes higher than 10,000/mm3 and blood lymphocytes lower than 350/mm3.
Toxoplasma encephalitis is a preventable disease when adequate prophylactic therapy is used and is relatively easy to treat in diagnosed
HIV patients. Unfortunately, this severe and deadly disorder is the HIV diagnostic disease in several patients, and our data support the
need for careful management of these patients, especially in those countries with a high toxoplasmosis prevalence where AIDS is
concurrent with economic and public health problems.
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INTRODUCTION
Central Nervous System (CNS) involvement is detected in 60%-90%
of autopsied AIDS patients in Brazil, with clinical significance in most
patients. Toxoplasma encephalitis (TE), rarely seen before AIDS, is the
most frequent CNS lesion in these patients (CHIMELLI et al., 1992).
Most cases are attributed to T. gondii cyst reactivation in the CNS
(DANNEMANN et al., 1992), but only 30-50% of AIDS patients with
serological evidence of contact with the agent develop the disease
(PORTER & SANDE, 1992). The estimated disease risk, 12-25%/year
(GRANT et al., 1990), is related to the incidence of toxoplasmosis in each
region, which is higher in France (BOSSI et al., 1998) and Brazil
(GUIMARÃES et al., 1993), to the absence of chemoprophylaxis
(BELANGER et al., 1999) and to low CD4+ counts (CROWE et al., 1991),
in addition to specific strain virulence (GROSS et al., 1997) or genetic
background (SUZUKI et al., 1996). TE generally presents as an insidious
focal CNS disease (LUFT & REMINGTON, 1988), but encephalitis with
meningeal irritation will occur in 5-10% of the patients (HOFMAN et al.,
1993). The diagnosis is presumptive in most cases, based on T. gondii-
specific antibodies in serum (PORTER & SANDE, 1992), CT or NMR
findings (ANTINORI et al., 1997), and response to therapy (HAVERKOS
et al., 1987). Serially rising specific T. gondii antibodies could suggest the
diagnosis (DEROUIN et al., 1996), but they are absent in 3-16% of patients,
probably due to acute infections in immunocompromised patients
(HAVERKOS, 1987). Antigen detection in CSF and serum (HAFID et
al., 1995) or urine (FACHADO et al., 1994) has been experimentally tested
but is not available in clinical practice. T. gondii DNA is detected by PCR
in 60-70% of patients, varying with biological source, with some false-
positive results, due to probably rupturing cysts without disease or technical
problems (EGGERS et al., 1995). Despite the increasing AIDS epidemics
and massive scientific research in the area, toxoplasmic encephalitis has
been diagnosed mainly by empiric therapeutic response and previous
serology, with a 10% error in these procedures (WINSTANLEY, 1995).
Research reports, which were highly frequent at the beginning of the HIV
epidemics, have not increased with the upsurge of AIDS, with few
algorithms suggested (SADLER et al., 1997). In this study we conducted
a retrospective analysis of toxoplasmic encephalitis patients from the main
hospital of São Paulo, Brazil, during two different stages of the epidemics,
i.e. in 1988 and 1991, looking for clinical and diagnostic management
procedures.
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METHODS
Sample and origin
A retrospective analysis of the files of the Instituto de Infectologia
Emilio Ribas was conducted after approval by the Ethics Committee.
This public institution is the main hospital for AIDS treatment in São
Paulo, Brazil, caring for 15-20% of AIDS patients during both periods,
with 30-40% patients presenting CNS diseases, mainly TE. The numbers
of AIDS patients in Brazil, their distribution and related CNS disease
and TE are listed in Table 1. Between 1988 and 1991 there was a three-
fold increase in AIDS patients, mainly in São Paulo. We selected at
random 192 files of AIDS patients with CNS involvement, 92 with clearly
defined TE and 92 with other well-defined CNS diseases except AIDS
dementia, covering the full years of 1988 and 1991.
Data definitions and recovery
A detailed form was prepared by two independent observers, with
demographic data, risk factors, time of HIV diagnosis, clinical diagnosis
and evolution data, and laboratory and radiology tests. We excluded
files with less than 50% of recoverable data (10 in 1988 and 15 in 1991),
with a total of 71 files concerning TE patients, 38 in 1988 and 33 in
1991. In these files, the AIDS diagnosis was based on the 1987 CDC
criteria, and TE was diagnosed in the presence of at least two of the
following findings: a history of neurological symptoms; neurological
signs at admission, or suggestive computed tomography (CT), all
associated with the introduction of anti-TE therapy. Using the same form,
we also analyzed files from AIDS patients with other CNS affections
such as cryptococcosis, tuberculosis, primary CNS lymphoma, and
aseptic and bacterial meningitis, for correction of eventually undefined
bias. A good therapeutic response was defined as improvement of clinical
condition, regression of neurological signs and symptoms, or
improvement of CT scans. Acute mortality was defined as death occurring
during the first week on the ward, and was considered to be due to TE if
defined by the medical team during any time of patient permanence in
the IIER. Laboratory tests and specific anti-Toxoplasma antibody tests
were performed by indirect immunofluorescence assays in CSF and blood
in the IIER laboratory upon medical request. CD4+ lymphocyte counts
and viral load were not tested at the institution at that time. CT was
performed when possible in better equipped hospitals.
Statistical analysis
The design of this work was previously defined in order to detect a
20% frequency difference, and data were considered significant when
the probability of similarity (P) was less than 0.05 (alpha error) and with
a power of 90% for all statistical tests applied, as reported in the tables.
Quantitative data were analyzed by the t test or ANOVA. When these
tests were not applied, the nonparametric Mann-Whitney or Kruskal
Wallis test was used. Frequency comparison was performed by the χ2
test with Yates correction or by Fisher’s exact test, with 95% confidence
intervals. Occasionally, the relation between events was analyzed by
Spearman rank correlation. All analyses were performed using the EpiInfo
6.0 or StatGraphics 5.0 software.
RESULTS
Demographic and HIV infection data are reported in Table 2, showing
change in risk factors for HIV from sexual contact to iv drug use, and a
small proportion of male homosexual transmission, with a doubling
female or heterosexual male rate in 1991 among TE AIDS patients. There
were no differences between groups in mean age at diagnosis or reported
time between beginning of symptoms and admission. There was a greater
lag time between HIV infection and clinical presentation in 1991.
Clinical presentation was similar during both periods, as shown in
Table 3, with most patient reporting or presenting fever, headache and
mental confusion. Coma and major clinical signs such as hemiplegias or
convulsions were less frequent, occurring in less than 30% of patients.
Laboratory tests also presented ill-defined results. Specific anti-
Toxoplasma antibodies in serum were searched in most patients in 1988,
71% (27/38), but in 1991, this test was performed only in 33.3% (11/33)
(p=0.0033). The presence of antibodies was detected in most patients,
with titers higher than 1/256 during both periods.
CSF analysis was performed in most patients during both periods,
89.5% (34/38) in 1988 and 90.9 (30/33) in 1991. Laboratory data
concerning these CSF samples are shown in Table 4. Anti-Toxoplasma
antibodies were tested in most CSF samples, with similar positivity at
low titers. No differences in cell type counts were observed (data not
shown).
Brain CT scans were performed in 52.6% (20/38) of patients in 1988
and in 57.6% (19/33) in 1991, with suggestive findings in most patients
and no differences between periods. Concomitant disease was observed
Table 1
Numerical distribution of AIDS patients in Brazil, in São Paulo and at IIER,
related to CNS diseases and Toxoplasma encephalitis, in 1988 and 1991
Number of AIDS Patients by Period
Groups 1988 1991
Brazil, total number of 3972 9470
AIDS patients
São Paulo 2312 5648
% of Brazil AIDS patients 58.2% 59.6%
IIER 614 1858
% of São Paulo AIDS patients 25.6% 32.9%
IIER
% of Brazil AIDS patients 15.5% 19.6%
CNS involvement 172 658
% of IIER AIDS patients 28.0% 35.4%
CNS involvement in IIER
% of Brazil AIDS patients 4.3% 6.9%
TE in IIER 97 374
% of CNS disease 56.4% 56.8%
TE in IIER
% of Brazil AIDS patients 2.4% 3.9%
Source: Epidemiology Service (SAME) of the Instituto de Infectologia Emílio Ribas.
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in most patients during both periods, with isolated TE in 21% (8/38) in
1988 and in 46% (15/33) in 1991. Treatment was started quickly during
both periods, usually with pyrimethamine in combination with
sulphadiazine, with folinic acid rescue. Side effects were similarly
detected during both periods, with a more frequent change to clindamycin
in 1991 (7/33) than in 1988 (2/38). A therapeutic response was detected
in 71.1% (27/38) of patients in 1988 and in 60.6% (20/33) in 1991.
Death was observed in 31.6% (12/38) of patients in 1988 and in
48.5% (16/33) in 1991. The mean time of death after admission was
24.9 days (95% CI 12.20-37.63) in 1988 and 25.9 days (95% CI 14.93-
36.95) in 1991. TE was directly responsible for most deaths, but some
patients died of other concomitant diseases, as shown in Table 5. We
pooled the TE patients into one group, looking for variables with a
significant value for death prognosis, as shown in Table 6, despite some
bias that could be introduced by this approach. The direct TE death rate
in the pooled population was 25.4% (18/71) and was significantly related
to the time of discovery of HIV infection, absence of fever and presence
of meningeal irritation at presentation, WBCs over 10,000/mm3 and blood
lymphocytes below 350/mm3. Other factors were suggestive of
involvement, such as old age (>46), low CSF glucose and absence of
CSF specific antibodies. Another interesting fact was the rate of women
evolving to death, 10 times higher than that for men, but these data were
not significant due to the small number of women in this series. Several
other available variables showed no significant results.
Comparison of pooled TE samples (71 files) with samples from other
CNS diseases (62 files) among AIDS patients during the same periods is
shown in Table 7. The files referred to 41 patients with cryptococcal
meningitis, 12 with undefined encephalitis, 5 with mycobacterial
meningitis, 1 with American trypanosomiasis encephalitis, and 1 with
mixed mycobacterial/cryptococcal meningitis. The data clearly showed
Table 2
Demographic data, natural history of HIV infection and risk factors, clinical
presentation signs and initial management of TE patients in 1988 and 1991
1988 1991 p
Age at admission 33.4 31.0 NS
Sex (as male/female ratio) 8.5 : 1 4 : 1 NS
Female/total 5/38 8/33 NS
Reported risk factors*
Drug users 13.2% 45.5% 0.0018
(n/total) 5/38 15/33
Heterosexual 60.5% 24.2% 0.001
Male homosexual 64.7% 14.8% 0.0002
(22/34) (4/27)
Unknown 2.6% 18.6% NS
1/38 6/33
Period between diagnosis 81.7±17.8 216.64±64 0.034
of HIV infection and TE
in days (mean ± SEM)
Reported period between 38.4 33.7 NS
beginning of symptoms
and admission (days)
* More than one risk factor was reported by some patients.
Table 3
Symptoms and Signs at admission in TE patients in 1988 and 1991*
1988(n=38) 1991(n=33)
Fever 66%(25) 55%(18)
Headache 54%(20) 64%(21)
Confusion 60%(23) 61%(20)
Torpor 11%(4) 24%(8)
Coma 16%(6) 11%(4)
Paresis/paresthesia 43%(13) 27%(9)
Plegia 13%(5) 30%(10)
Convulsions 34%(13) 33%(11)
Meningeal irritation 18%(7) 21%(7)
Visual disturbance 18%(7) 15%(5)
*There were no differences between the two periods
Table 4
CSF analysis of TE patients during the two study periods
Year 1988 1991 p
(n/total) (34/38) (30/33)
Protein (mg%) 185 243 NS
mean (95% CI) (108-206) (162-324)
Glucose (mg%) 42 42 NS
Mean (95% CI) (37-47) (36-48)
Cells/ml 45 58 NS
Mean (95% CI) (13-102) (2-118)
Anti-Toxoplasma antibodies % 81.2% 61.5% p=0.0033
(Positive/n tested) (25/31) (16/26)
Table 5
Evolution of TE patients in 1988 and 1991
1988 1991
Survivors after 68.4 51.5 NS
1st admission (%)(n/total) (26/38) (17/33)
Deaths due to TE at 21.1 30.3 NS
1st admission (%)(n/total) (8/38) (10/33)
Deaths not attributable to 10.5 18.2 NS
TE at 1st admission (%)(n/total) (4/38) (6/33)
Proportion of TE deaths/ total 66.7 62.5 NS
deaths (%)(n/total) (8/12) (10/16)
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were similar to those found by other authors in Brazil (CHIMELLI et al.,
1992, WAINSTEIN et al., 1992) and in other countries with a high
incidence of toxoplasmosis (REITER-OWONA et al., 1998), with a
relatively high incidence of TE in São Paulo AIDS patients, as compared
to other countries with low toxoplasmosis incidence, such as the US,
attributed to cultural health habits (LUFT & CASTRO, 1991). Although
the management of our TE patients was essentially similar in both periods,
some differences occurred. The most impressive fact was the proportion
of patients without a serological diagnosis of toxoplasmosis in 1991, with
the attending physician making the diagnosis without these data. This
approach was based on various reported guidelines, mainly in terms of
algorithms, which suggest that response to therapy or CSF fluid analysis
could suffice for diagnosis, despite several reports of failure in these two
approaches (SADLER et al., 1998). Interestingly, more therapy changes
occurred in 1991, with alternative regimens being frequently introduced.
CSF was collected from most patients during both periods despite the
risk, with most data being inconclusive, also in terms of the search for
specific anti-Toxoplasma antibodies. CT and other radiological tests were
performed when possible during both periods, with high resolution, as
reported elsewhere (ANTINORI et al., 1997). In 1991, TE was considered
a minor and easily treatable AIDS complication despite the large number
of deaths observed. Despite these problems, the diagnosis of TE was
adequately presumed and performed during both periods, with a clear
identification of other CNS infections based on clinical and laboratory
findings, as observed in the joined analysis.
Our hospital-based approach allowed us to suggest some clinical
predictors of early death, which could be attributed to the severity of
either TE or AIDS. Some of those predictors, such as the absence of
fever, may be related to the severe immunodeficiency induced by AIDS,
and others, such as generalized signs of brain involvement or low CSF
glucose levels, could be ascribed to the severity of opportunistic disease.
There are few reports on the acute prognostic factors in TE, dealing
mostly with response to treatment (LUFT et al., 1993). Most prognostic
studies deal with long-term outcome (BELANGER et al., 1999) despite
the high mortality observed during the acute disease in our sample.
Toxoplasma encephalitis can be prevented by adequate prophylactic
therapy and is relatively easy to treat in diagnosed AIDS patients using
appropriate primary and secondary drug regimens (ANTINORI et al.,
1995). Unfortunately, this severe and deadly disease is the disease that
leads to a diagnosis of AIDS in several patients, and should be considered
as a powerful enemy (OKSENHENDLER et al., 1995), especially in
those countries where AIDS is concurrent with economic and public
health problems. Accurate clinical studies should be performed in order
to provide a feasible diagnostic and prognostic approach to toxoplasmic
encephalitis for the prevention of acute morbidity and mortality.
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Table 6
Death prognostic factors analyzed in the joint populations. Significance is
expressed as odds ratio (OR) over 1, with p<0.10
Factors OR p
More than 9 months of knowledge of 6 0.0147
HIV infection at admission
Absence of fever at presentation 3 0.028
Blood lymphocytes lower than 350/mm3 6 0.032
Presence of meningeal irritation signs 4 0.047
White blood cells higher than 10000/mm3 7 0.04
Age over 46 11* 0.070
CSF Glucose levels lower than 35 mg% 2* 0.058
Absence of anti-Toxoplasma abs in CSF 3* 0.083
* Suggestive data only (0.05>p>0.10).
Table 7
Comparison of joint TE patients with AIDS patients with other CNS diseases
TE Other CNS p
 disease than TE
Disease as presenting AIDS 26.8% 50.8% 0.005
diagnosis (<1 month)
Headache 16.9% 61.3% 0.008
Mental confusion 60.6% 27.4% 0.0002
Stupor 16.9% 3.2% 0.02
Absence of focal 45.1% 74.2% 0.0012
neurological signs
Myoclonal movements 33.8% 17.7% 0.036
and convulsions
High titer in serological tests 33.3% 5.9% 0.0001
for toxoplasmosis (> 1/4000)
Presence of anti-Toxoplasma 72.4% 44.7% 0.007
antibodies in CSF
Death within 1 week of admission 21.4% 50% 0.03
that these diseases presented a more diffuse brain involvement, without
focal signs or conscience deficits, but with extreme severity, resulting in
more early deaths than among TE patients. High specific anti-Toxoplasma
antibody titers were more prevalent in TE but occurred also in other
CNS diseases. These antibodies were also more frequent in CSF from
TE patients but were also present in a significant number of CSF samples
from patients with other CNS diseases.
DISCUSSION
Our data clearly show that TE was one of the most important AIDS-
related diseases, inducing high lethality and morbidity during both periods
in Brazil. When comparing the two periods, we found several AIDS
epidemic-correlated demographic differences, but the main findings related
to the agent and its disease, TE, were similar in both periods. Our data
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RESUMO
Encefalite por Toxoplasma em pacientes com AIDS em São Paulo,
Brasil, durante 1988 e 1991. Análise retrospectiva comparativa
Uma análise retrospectiva foi conduzida em pacientes com encefalite
por Toxoplasma do Instituto de Infectologia Emílio Ribas, o principal
hospital de AIDS em São Paulo, Brasil, durante dois períodos distintos,
em diferentes níveis da epidemia de HIV. Existem diferenças
demográficas relativas aos períodos, sendo a apresentação clínica e
eficiência diagnóstica similar nos dois períodos. O diagnóstico era
confirmado por dados tomográficos e resposta à terapia, com clara
distinção de outras infecções do SNC, baseadas em dados clínicos e
laboratoriais. Estudos sorológicos específicos foram menos executados
em 1991, com maior freqüência de mudanças na terapia. A mortalidade
aguda direta por toxoplasmose foi alta em ambos os períodos, 8/38 em
1988 e 10/33 em 1991. A taxa de mortalidade aguda conjunta nos dois
períodos foi de 25,4% (18/71), relacionando-se ao tempo de infecção
pelo HIV, ausência de febre, presença de sinais de irritação meníngea na
apresentação, leucocitose acima de 10000/mm3 e número de linfócitos
circulantes inferior a 350/mm3. A encefalite por Toxoplasma é uma
doença com profilaxia e tratamento simples em pacientes com diagnóstico
prévio de infecção pelo HIV. Infelizmente, esta doença grave e letal é a
doença diagnóstica da infecção pelo HIV em muitos pacientes, e nossos
dados reforçam que deve ser manuseada clinicamente com cuidado,
especialmente naqueles países com maior prevalência de toxoplasmose
onde a AIDS está associada a problemas econômicos e de Saúde Pública.
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